Recent News
Powered by Alpha Vantage
No recent news found.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
52W High
$28.73
52W Low
$10.80
MA Status:
50D: Above
200D: Above
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
Attractive
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
0.13
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
0.06
EV/Revenue (<3 favorable)
550.94
P/S (TTM) (<3 favorable)
1100.89
P/B (<3 favorable)
2.33
Ownership
BalancedSource: Overview
Insiders (1–5% typical)
27.19%
Institutions (25–75% balanced)
68.12%
Shares Outstanding
14,475,900
Float
7,712,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
200,000
Gross Profit (TTM)
-200,607,008
EPS (TTM)
119.02
Profit Margin (>10% good)
8614.85%
Operating Margin (TTM) (higher better)
-1162.32%
ROE (TTM) (>15% strong)
0.41%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentumValue
1.7658
Previous
1.9485
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025